Year: 2024

Yanick J. Crow has been selected as the 2024 ICIS-Pfizer Award for Excellence in Interferon and Cytokine Research in recognition for his groundbreaking research on Type I Interferonopathies which has revolutionized the fields of basic and clinical immunology with phenomenal clinical and biological implications. Professor Crow is recognized as one of the top three scientists in the field of human inborn errors of immunity and the founder of the rapidly growing and revolutionary field of “Type I interferonopathies,” making him a most deserving recipient for the ICIS-Pfizer Award for Excellence in Cytokine & Interferon Research. [READ MORE]

Stefan Rose-John is recognized as the 2024 ICIS-BioLegend William E. Paul Award winner in recognition for his seminal contributions to the field of cytokine biology. With a primary focus on the IL-6 cytokine family, his fundamental research has pioneered several paradigm-shifting discoveries, which have steered understanding of IL-6 in physiology and pathophysiology. Moreover, these insights have informed refinements affecting how target IL-6 for therapy. By presenting this Award, which is generously sponsored by BioLegend, the ICIS recognizes Professor Rose-John as one of a rare breed of scientists who has excelled in discovery science, achieved success as an entrepreneur, and translated his basic scientific discoveries into treatments that directly ameliorate patients’ lives. [READ MORE]

Laura Mackay has been selected as the 2024 ICIS-Luminex John R. Kettman Award for Excellence in Cytokine & Interferon Research in recognition for her outstanding work on memory T cell populations and the cytokines that control them. Professor Mackay’s discoveries have resulted in dramatic paradigm shifts and have contributed enormously to the T cell field, spawning a new focus on tissue immunity. Her accomplishments are shaping and redefining how we understand cellular immune responses and have driven a new field of T cell immunology. These accomplishments indeed far exceed her designated “mid-career” stage. [READ MORE]